Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Elanco Animal Health IncELAN · Entity 3457 | Director | November 29, 2024 | December 03, 2024 |
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Senior Vice President | February 15, 2023 | February 17, 2023 |
| IMMUCELL CORP /DE/ICCC · Entity 6837 | Director | April 15, 2026 | April 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Elanco Animal Health Inc
Report date November 29, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,838 |
Reported balance
After 2024-11-29 transaction · row 1
1 source rowRow 1 · 2024-11-29 · Grant · Acquired 13,838 · Balance 13,838 F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.
IDEXX LABORATORIES INC /DE
Report date February 15, 2023 · Filed February 17, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,379.8492 |
Ending reported balance
After 2023-02-16 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-02-15 · Grant · Acquired 1,000 · Balance 8,379.8492 Row 2 · 2023-02-15 · Sale · Disposed 1,000 · Balance 7,379.8492 F1: Represents the weighted average price of the shares sold ranging from a low of $510.00 to a high of $510.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 3 · 2023-02-16 · Exercise / conversion · Acquired 10 · Balance 7,389.8492 Row 4 · 2023-02-16 · Sale · Disposed 10 · Balance 7,379.8492 |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.54 · Expires 2025-02-13 | Direct | 3,736 |
Reported balance
After 2023-02-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-02-15 · Exercise / conversion · Disposed 1,000 · Balance 3,736 F4: Not applicable. F3: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $79.54 · Expires 2025-02-13 | Direct | 3,726 |
Reported balance
After 2023-02-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-02-16 · Exercise / conversion · Disposed 10 · Balance 3,726 F4: Not applicable. F3: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. |
| Common StockSEC Table I · non-derivative | Indirectby spouse | 100 |
Reported balance
Holding disclosure · report date 2023-02-15 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 100 F2: The reporting person disclaims beneficial interest of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average price of the shares sold ranging from a low of $510.00 to a high of $510.10 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F2: The reporting person disclaims beneficial interest of the shares of common stock held by her spouse except to the extent of her pecuniary interest therein.
F3: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F4: Not applicable.
IMMUCELL CORP /DE/
Report date April 15, 2026 · Filed April 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non Qualified Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2036-04-15 | Direct | 17,899 |
Reported balance
After 2026-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-15 · Grant · Acquired 17,899 · Balance 17,899 F1: The stock option vests as follows: 5,966 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares becoming exercisable on April 15, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as follows: 5,966 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares becoming exercisable on April 15, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 14, 2020 Filed Feb 20, 2020 02:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 212 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004371 · doc1.xml · nonDerivative · entry 3 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,676 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 221 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004371 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2020 Filed Feb 20, 2020 02:34 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 188 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-004371 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 21 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 31, 2019. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 22:15 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 7,780 | Not disclosed Strike: $64.24 | Not disclosed |
DisclosureSEC source: 0001567619-19-022479 · doc1.xml · derivative · entry 3 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,780 shares Expires 2024-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Not applicable. F2 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,890 shares on June 1, 2019, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 22:15 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 7,780 | $64.24 | $499,787.20 |
DisclosureSEC source: 0001567619-19-022479 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,034 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 42 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 28, 2019 and September 30, 2019. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-012690 · doc1.xml · derivative · entry 4 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,012 Underlying: Common Stock · 466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: These restricted stock units are part of a grant made to the reporting person on June 1, 2014 that have vested. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F5 · price: Not applicable. F4 · derivative.exercise_date: These restricted stock units are part of a grant made to the reporting person on June 1, 2014 that have vested. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F4 · derivative.expiration_date: These restricted stock units are part of a grant made to the reporting person on June 1, 2014 that have vested. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 118 | $249.77 | $29,472.86 |
DisclosureSEC source: 0001567619-19-012690 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,212 F2 · price: Closing price of Issuer's common stock on the NASDAQ market on May 31, 2019. Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 21:02 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 466 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012690 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 32 shares of Issuer common stock purchased under the IDEXX Employee Stock Purchase Plan on March 29, 2019. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 211 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-004925 · doc1.xml · derivative · entry 13 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,478 Underlying: Common Stock · 211 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: 7. Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F10 · price: Not applicable. F9 · derivative.exercise_date: 7. Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. F9 · derivative.expiration_date: 7. Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2019. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 212 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-004925 · doc1.xml · derivative · entry 12 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,689 Underlying: Common Stock · 212 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F10 · price: Not applicable. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2018. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 221 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-004925 · doc1.xml · derivative · entry 11 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,901 Underlying: Common Stock · 221 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. F10 · price: Not applicable. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2017. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 188 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-004925 · doc1.xml · derivative · entry 10 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,122 Underlying: Common Stock · 188 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F10 · price: Not applicable. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2016. The number of RSUs have been adjusted to reflect the 2-for-1 stock split of Issuer common stock that occurred on June 15, 2015 (the "Stock Split"). Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 906 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-004925 · doc1.xml · derivative · entry 9 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,310 Underlying: Common Stock · 906 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F10 · price: Not applicable. F5 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F5 · derivative.expiration_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 483 | Not disclosed Strike: $206.94 | Not disclosed |
DisclosureSEC source: 0001567619-19-004925 · doc1.xml · derivative · entry 8 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483 Underlying: Common Stock · 483 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable on the fifth anniversary of the date of grant. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 8,366 | Not disclosed Strike: $206.94 | Not disclosed |
DisclosureSEC source: 0001567619-19-004925 · doc1.xml · derivative · entry 7 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,366 Underlying: Common Stock · 8,366 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2020. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 233 | $206.94 | $48,217.02 |
DisclosureSEC source: 0001567619-19-004925 · doc1.xml · nonDerivative · entry 5 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,832 Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 211 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-004925 · doc1.xml · nonDerivative · entry 4 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 212 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-004925 · doc1.xml · nonDerivative · entry 3 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 221 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-004925 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,642 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 23:09 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 188 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-004925 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,421 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 74 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on June 28, 2018, September 30, 2018 and December 31, 2018. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 21:07 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-18-027151 · doc1.xml · derivative · entry 4 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,404 Underlying: Common Stock · 466 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: These restricted stock units are part of a grant made to the reporting person on June 1, 2014 that have vested. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F4 · price: Not applicable. F3 · derivative.exercise_date: These restricted stock units are part of a grant made to the reporting person on June 1, 2014 that have vested. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. F3 · derivative.expiration_date: These restricted stock units are part of a grant made to the reporting person on June 1, 2014 that have vested. Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The restricted stock units vest in five equal annual installments, beginning on the first anniversary of the date of grant. The number of restricted stock units reported was adjusted to reflect a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 21:07 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 113 | $215.36 | $24,335.68 |
DisclosureSEC source: 0001140361-18-027151 · doc1.xml · nonDerivative · entry 2 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,159 F1 · price: Closing price of Issuer's common stock on the NASDAQ market on June 1, 2018. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 21:07 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 466 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-027151 · doc1.xml · nonDerivative · entry 1 Turner Kathy V · CIK 0001740719 · Corporate Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.